GlassScriptPhysician profile
Anna Akopyan
NPI 1134895899
$15,733.52
in general payments reported to CMS, 2019-2025
66 companies · $5,316 in 2025
The $5,316 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.86 · 2022: $2,458 · 2023: $3,891 · 2024: $3,995 · 2025: $5,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,718.49 |
| Education | $1,484.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,443.85 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $1,321.95 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Celgene Corporation | $1,016.81 | 2022-2025 | Reblozyl, Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $769.35 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $742.28 | 2023-2025 | Enhertu, Faslodex, Calquence |
| Astellas Pharma US INC | $661.55 | 2022-2025 | Xtandi, Vyloy, Xospata |
| Novartis Pharmaceuticals Corporation | $639.79 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $617.49 | 2022-2025 | |
| Genzyme Corporation | $589.86 | 2022-2025 | |
| Pfizer INC. | $518.35 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $452.67 | 2022-2025 | Xpovio |
| Seagen INC. | $448.93 | 2022-2025 | Adcetris, Padcev, Tivdak |
| E.R. Squibb & Sons, L.L.C. | $448.84 | 2022-2025 | Opdivo, Opdualag, Orencia |
| Takeda Pharmaceuticals U.S.A., INC. | $423.57 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Genentech USA, INC. | $420.35 | 2022-2025 | Phesgo, Venclexta, Itovebi |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $361.71 | 2023-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.78 | 2022-2025 | Gilotrif |
| Pharmaessentia USA Corporation | $327.20 | 2022-2025 | Besremi |
| Daiichi Sankyo INC. | $283.86 | 2022-2025 | Enhertu |
| Abbvie INC. | $282.19 | 2022-2025 | Venclexta |
| Lilly USA, LLC | $261.53 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $259.71 | 2022-2025 | |
| Blueprint Medicines Corporation | $219.95 | 2021-2024 | Ayvakit |
| Tersera Therapeutics LLC | $210.32 | 2022-2025 | Xermelo, Zoladex, Quzyttir |
| Array Biopharma INC | $207.18 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Genmab U.S., INC. | $192.68 | 2023-2025 | Epkinly |
| Amgen INC. | $180.29 | 2022-2025 | Imdelltra (Amg757), Lumakras |
| Sobi, INC | $148.31 | 2022-2025 | |
| Stemline Therapeutics INC. | $135.64 | 2023-2025 | Orserdu |
| Foundation Medicine, INC. | $124.76 | 2023 | |
| Glaxosmithkline, LLC. | $123.23 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Puma Biotechnology, INC. | $118.24 | 2022-2024 | |
| Exelixis INC. | $94.29 | 2023-2024 | Cabometyx |
| Taiho Oncology, INC. | $92.31 | 2023-2025 | |
| Geron Corporation | $88.52 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $73.45 | 2022-2024 | |
| Immunocore Limited | $73.21 | 2024 | Kimmtrak |
| Beigene USA, INC. | $68.89 | 2023-2024 | Brukinsa |
| Immunogen, INC. | $66.74 | 2023 | Elahere |
| Beone Medicines USA, INC. | $60.50 | 2025 | Tevimbra |
| Ge Healthcare | $57.88 | 2022 | |
| Legend Biotech USA INC. | $56.22 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $54.63 | 2024-2025 | |
| Emd Serono, INC. | $49.27 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $47.39 | 2023-2024 | Qinlock |
| Acrotech Biopharma INC. | $46.82 | 2021-2025 | Beleodaq |
| Morphosys, US INC. | $41.93 | 2022-2023 | Monjuvi |
| Mirati Therapeutics, INC. | $41.48 | 2024 | Krazati |
| Kyowa Kirin, INC. | $40.23 | 2022 | |
| Chiesi USA, INC. | $39.80 | 2023-2024 | Ferriprox |
| Dendreon Pharmaceuticals LLC | $29.64 | 2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $28.92 | 2024 | Monoferric |
| Progenics Pharmaceuticals, INC. | $26.78 | 2025 | |
| Sumitomo Pharma America, INC. | $26.42 | 2023 | Orgovyx |
| Servier Pharmaceuticals LLC | $24.63 | 2025 | |
| Adc Therapeutics America, INC. | $24.12 | 2025 | |
| Kite Pharma, INC. | $23.72 | 2024 | Yescarta |
| Clovis Oncology, INC. | $23.64 | 2022 | |
| Caris Mpi, INC. | $22.56 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $22.21 | 2023 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $21.97 | 2022 | |
| Coherus Oncology, INC. | $21.95 | 2025 | Loqtorzi |
| Octapharma USA, INC. | $18.76 | 2023 | Panzyga |
| Rigel Pharmaceuticals, INC. | $17.47 | 2022 | |
| Spectrum Pharmaceuticals INC. | $13.55 | 2023 | Rolvedon |
| Tolmar Pharmaceuticals, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Akopyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.